Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 117
Titolo Data di pubblicazione Autore(i) File
EFFICACY OF A IDARUBICIN, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE ARABINOSIDE AS SALVAGE THERAPY IN RELAPSING OR RESISTANT UNFAVORABLE LYMPHOMA 1-gen-1998 Brusamolino, E; Passamonti, Francesco; Pagnucco, G; Castagnola, C; Lazzarino, Mario; Bernasconi, Carlo
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY. 1-gen-1999 Balzarotti, M.; Grisanti, S.; Granzow, K.; Saladini, A.; Sala, A.; Nozza, A.; Molteni, A.; Passamonti, Francesco; CARLO STELLA, C.; Santoro, A.; Siena, S.
EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS 1-gen-2000 Passamonti, Francesco; Brusamolino, E; Lazzarino, Mario; Barat, C; Klersy, C; Orlandi, E; Canevari, A; Castelli, G; Merante, S; Bernasconi, Carlo
TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY 1-gen-2000 Brusamolino, E; Lunghi, F; Orlandi, E; Astori, C; Passamonti, Francesco; Barat, C; Pagnucco, G; Baio, A; Lazzarino, Mario; Bernasconi, Carlo
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. 1-gen-2001 Vassallo, C.; Passamonti, Francesco; Merante, S.; Ardigò, M.; Nolli, G.; Mangiacavalli, S.; Borroni, Giovanni
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA 1-gen-2002 Bernasconi, Paolo; Boni, M.; Cavigliano, P. M. .; Calatroni, S.; Brusamolino, E.; Passamonti, Francesco; Pistorio, A.; Giardini, I.; Rocca, B.; Caresana, M.; Lazzarino, M.; Brernasconi, C.
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 1-gen-2002 Passamonti, Francesco; Malabarba, L; Orlandi, E; Pascutto, Cristiana; Brusamolino, E; Astori, C; Baratè, C; Canevari, A; Corso, A; Bernasconi, Paolo; Cazzola, Mario; Lazzarino, Mario
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN. 1-gen-2003 Passamonti, Francesco; Lazzarino, Mario
Leucemia mieloide cronica e sindromi mieloproliferative croniche 1-gen-2003 Brusamolino, E; Passamonti, Francesco
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 1-gen-2003 Passamonti, Francesco; Malabarba, L; Orlandi, E; Baratè, C; Canevari, A; Brusamolino, E; Bonfichi, M; Arcaini, Luca; Caberlon, S; Pascutto, Cristiana; Lazzarino, Mario
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 1-gen-2003 Passamonti, Francesco; Vanelli, L; Malabarba, L; Rumi, Elisa; Pungolino, E; Malcovati, Luca; Pascutto, Cristiana; Morra, E; Lazzarino, Mario; Cazzola, Mario
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 1-gen-2004 Passamonti, Francesco; Pietra, Dario; Malabarba, L; Rumi, Elisa; DELLA PORTA, MATTEO GIOVANNI; Malcovati, Luca; Bonfichi, M; Pascutto, Cristiana; Lazzarino, Mario; Cazzola, Mario
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. 1-gen-2004 Arcaini, Luca; Orlandi, E; Scotti, M; Brusamolino, E; Passamonti, Francesco; Burcheri, S; Colombo, N; Vanelli, L; Sbalzarini, G; Lazzarino, Mario
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 1-gen-2004 Passamonti, Francesco; Rumi, Elisa; Malabarba, L; Arcaini, Luca; Orlandi, E; Brusamolino, E; Pascutto, C; Cazzola, Mario; Lazzarino, Mario
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 1-gen-2004 Passamonti, Francesco; Cazzola, Mario
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 1-gen-2004 Passamonti, Francesco; Rumi, Elisa; Pungolino, E; Malabarba, L; Bertazzoni, P; Valentini, M; Orlandi, E; Arcaini, Luca; Brusamolino, E; Pascutto, C; Cazzola, Mario; Morra, E; Lazzarino, Mario
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 1-gen-2005 Kralovics, R; Teo, Ss; Buser, As; Brutsche, M; Tiedt, R; Tichelli, A; Passamonti, Francesco; Pietra, D; Cazzola, Mario; Skoda, Rc
Pityriasis roseaelike eruption during treatment with imatinib mesylate: Description of 3 cases 1-gen-2005 Borroni, Giovanni; Prestinari, F; Roveda, E; Barbagallo, T; Bellani, E; Vassallo, C; Orlandi, E; Passamonti, Francesco; Borroni, G.
A gain-of-function mutation of JAK2 in myeloproliferative disorders 1-gen-2005 Kralovics, R; Passamonti, Francesco; Buser, As; Teo, Ss; Tiedt, R; Passweg, Jr; Tichelli, A; Cazzola, Mario; Skoda, Rc
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 1-gen-2005 Passamonti, Francesco; Pietra, D; Rumi, Elisa; Arcaini, Luca; DELLA PORTA, MATTEO GIOVANNI; Malcovati, Luca; Pascutto, C; Lazzarino, Mario; Cazzola, Mario
Mostrati risultati da 1 a 20 di 117
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile